Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast vs salmeterol for exercise-induced bronchoconstriction in pediatric asthma (cross-over)
2004-004709-53Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of montelukast and salmeterol in asthma and exercise-induced bronchospasm (EIB) (2 arms), sponsored by Merck & Co. Primary endpoint: Maximum percent fall in FEV1 after exercise before beta-agonist administration. Started Aug 2005; status: completed.
02
Drugs
montelukastsalmeterol
03
Conditions
asthmaexercise-induced bronchospasm (EIB)
Beyond the preview
Go deeper on 2004-004709-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004709-53.